CA-125

Cancer Antigen 125

Tumor Markers

What is Cancer Antigen 125?

Cancer Antigen 125 (CA-125) is a glycoprotein encoded by the MUC16 gene that is expressed on the surface of cells derived from coelomic epithelium, including the mesothelial lining of the peritoneum, pleura, and pericardium, as well as the epithelium of the fallopian tubes, endometrium, and endocervix. CA-125 is shed from cell surfaces into the bloodstream and can be measured via immunoassay. It was first identified in 1981 using monoclonal antibody OC125, which recognized an antigen consistently elevated in the serum of patients with epithelial ovarian cancer.

CA-125 is most widely used as a serum biomarker for monitoring treatment response and detecting recurrence in patients with epithelial ovarian cancer, particularly serous carcinomas. It is not recommended as a standalone screening tool for ovarian cancer in the general population because of its limited sensitivity in early-stage disease and its poor specificity—many benign conditions also elevate CA-125. However, in combination with transvaginal ultrasound, it may have a role in screening high-risk populations. Serial measurements are generally more informative than single values.

Why It Matters

CA-125 is the most established serum biomarker for epithelial ovarian cancer, used primarily to monitor treatment response and detect disease recurrence. A rising CA-125 after treatment can signal relapse months before imaging findings appear. However, CA-125 has important limitations: it is elevated in only about 80% of advanced ovarian cancers and fewer than 50% of early-stage cases. Many benign gynecological and non-gynecological conditions can raise CA-125, so results must always be interpreted in clinical context. In premenopausal women, benign elevations are particularly common.

Normal Reference Ranges

Group	Range	Unit
Adults (general)	0–35	U/mL
Premenopausal women	0–35	U/mL
Postmenopausal women	0–20	U/mL

Reference ranges may vary by laboratory. Always compare results to the ranges provided by your testing facility.

What High CA-125 Levels Mean

Common Causes

Epithelial ovarian cancer (especially serous carcinoma)
Endometriosis
Uterine fibroids
Pelvic inflammatory disease
Menstruation and first trimester pregnancy
Liver cirrhosis and ascites
Peritoneal, pleural, or pericardial inflammation
Endometrial, fallopian tube, and primary peritoneal cancers
Pancreatitis and pancreatic cancer
Congestive heart failure

Possible Symptoms

Abdominal bloating or swelling
Pelvic or abdominal pain
Feeling full quickly when eating
Urinary urgency or frequency
Unexplained weight loss or gain
Fatigue
Back pain

What to do: Elevated CA-125 requires clinical correlation. In postmenopausal women with an adnexal mass, elevated CA-125 strongly suggests malignancy and warrants surgical evaluation. In premenopausal women, benign causes should be excluded first. For patients with known ovarian cancer, serial CA-125 measurements are used to assess treatment response—a 50% decline correlates with response, while a doubling from nadir suggests progression. Additional imaging (transvaginal ultrasound, CT) and possibly further biomarkers (HE4, ROMA score) may be ordered.

What Low CA-125 Levels Mean

Common Causes

Normal physiological state (no clinical concern)
Successful treatment of ovarian cancer
Non-mucinous ovarian cancers may not produce CA-125

Possible Symptoms

No symptoms are associated with low CA-125

What to do: Low or undetectable CA-125 is normal and generally reassuring. In ovarian cancer patients, declining CA-125 toward normal during chemotherapy indicates treatment response. However, a normal CA-125 does not exclude ovarian cancer—some histological subtypes (mucinous, clear cell) may not elevate CA-125 even in advanced disease.

When Is CA-125 Testing Recommended?

Monitoring treatment response in epithelial ovarian cancer
Surveillance for ovarian cancer recurrence after treatment
Evaluating an adnexal mass in postmenopausal women
Screening high-risk women (BRCA1/2 mutation carriers) in combination with ultrasound
Assessing response to neoadjuvant chemotherapy in ovarian cancer

Frequently Asked Questions

CA-125 alone is not a reliable early-detection tool. It is elevated in fewer than 50% of stage I ovarian cancers and can be raised by many benign conditions. Serial measurements combined with transvaginal ultrasound may improve detection in high-risk populations, but routine screening of the general population with CA-125 is not currently recommended by major guidelines.

CA-125 is produced by mesothelial cells lining body cavities, not only by ovarian cancer cells. Endometriosis, uterine fibroids, pelvic inflammatory disease, liver cirrhosis, heart failure, menstruation, and early pregnancy can all raise CA-125. In premenopausal women, benign elevations are common and should be evaluated before assuming malignancy.

During chemotherapy, CA-125 is typically measured before each treatment cycle (every 2–3 weeks). After treatment completion, it is usually checked every 2–3 months for the first 2 years, then every 3–6 months for the following 3 years. Frequency depends on clinical context and physician preference.

Related Biomarkers

CA 19-9Cancer Antigen 19-9 CEACarcinoembryonic Antigen

Want your CA-125 levels analyzed?

Upload your lab results for an instant AI-powered breakdown of all your biomarkers.

Upload Lab Results →

Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Reference ranges may vary between laboratories. Always consult your healthcare provider for interpretation of your specific test results.